Champions Oncology (CSBR) Depreciation & Amortization (CF) (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Depreciation & Amortization (CF) of $341000.0 in Q1 2026, down 4.48% quarter-over-quarter from $357000.0 in Q4 2025, and down 14.32% on a YoY basis from $398000.0 in Q1 2025.
Champions Oncology (CSBR) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Champions Oncology's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $341000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 14.32% year-over-year to $341000.0; the TTM figure through Jan 2026 stood at $1.4 million (down 14.86% YoY), while the FY2025 annual figure was $1.6 million, down 12.16% from the prior year.
- Depreciation & Amortization (CF) was $341000.0 for Q1 2026 at Champions Oncology, down from $357000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $583000.0 in Q2 2023 to a low of $341000.0 in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $457235.3 across 5 years, with a median of $449000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) soared 87.46% in 2022, then retreated 21.61% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $560000.0 in 2022, then retreated by 13.57% to $484000.0 in 2023, then declined by 17.56% to $399000.0 in 2024, then dropped by 10.53% to $357000.0 in 2025, then retreated by 4.48% to $341000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $341000.0 (Q1 2026), $357000.0 (Q4 2025), and $358000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 429,663.65 |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | 341,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 341,000.00 |
| Jan 31, 2026 | 341,000.00 |
| Oct 31, 2025 | 357,000.00 |
| Oct 31, 2025 | 357,000.00 |
| Jul 31, 2025 | 358,000.00 |
| Jul 31, 2025 | 358,000.00 |
| Apr 30, 2025 | 394,000.00 |
| Apr 30, 2025 | 394,000.00 |
| Jan 31, 2025 | 398,000.00 |
| Jan 31, 2025 | 398,000.00 |
| Oct 31, 2024 | 399,000.00 |
| Oct 31, 2024 | 399,000.00 |
| Jul 31, 2024 | 449,000.00 |
| Jul 31, 2024 | 449,000.00 |
| Apr 30, 2024 | 457,000.00 |
| Apr 30, 2024 | 457,000.00 |
| Jan 31, 2024 | 481,000.00 |
| Jan 31, 2024 | 481,000.00 |
| Oct 31, 2023 | 484,000.00 |
| Oct 31, 2023 | 484,000.00 |